Anakinra for palmoplantar pustulosis: results from a randomized, double‐blind, multicentre, two‐staged, adaptive placebo‐controlled trial (APRICOT)*

Cro, Suzie; Cornelius, Victoria; Pink, Andrew E.; Wilson, Rebecca; Pushpa-Rajah, Angela; Patel, Prakash A.; Abdul‐Wahab, Alya; August, Suzannah; Azad, J.; Becher, Gabrielle; Chapman, Anna; Dunnil, G.; Ferguson, Adam; Fogo, A.; Ghaffar, S.A.; Ingram, John R.; Kavakleiva, S.; Ladoyanni, Evmorfia; Leman, Joyce; Macbeth, A. E.; Makrygeoegou, A.; Parslew, Richard; Ryan, Alan J.; Sharma, Amit; Shipman, A. R.; Sinclair, Catriona; Wachsmuth, Rachel C.; Woolf, Richard; Wright, Andrew; McAteer, Helen; Barker, Jonathan; Burden, A. David; Griffiths, Christopher E.M.; Reynolds, Nick J.; Warren, Richard B; Lachmann, Helen; Capon, Francesca; Smith, Catherine

doi:10.1111/bjd.20653

Cited by 25 publications

(23 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Table 3 contains information about the main recent clinical trials regarding treatment of PP [ 126 , 127 , 128 , 129 , 130 , 131 , 132 , 133 , 134 , 135 , 136 , 137 , 138 , 139 , 140 , 141 , 142 , 143 , 144 , 145 , 146 , 147 , 148 , 149 , 150 ]. Ongoing clinical trials and other completed studies not included in Table 3 are reported in Table 4 .…”

Section: Treatmentmentioning

confidence: 99%

Pustular Psoriasis: From Pathophysiology to Treatment

Genovese

Moltrasio

Cassano³

et al. 2021

Biomedicines

View full text Add to dashboard Cite

Pustular psoriasis (PP) is a clinicopathological entity encompassing different variants, i.e., acute generalized PP (GPP), PP of pregnancy (impetigo herpetiformis), annular (and circinate) PP, infantile/juvenile PP, palmoplantar PP/palmoplantar pustulosis, and acrodermatitis continua of Hallopeau (ACH), which have in common an eruption of superficial sterile pustules on an erythematous base. Unlike psoriasis vulgaris, in which a key role is played by the adaptive immune system and interleukin (IL)-17/IL-23 axis, PP seems to be characterized by an intense inflammatory response resulting from innate immunity hyperactivation, with prominent involvement of the IL-36 axis. Some nosological aspects of PP are still controversial and debated. Moreover, owing to the rarity and heterogeneity of PP forms, data on prognosis and therapeutic management are limited. Recent progresses in the identification of genetic mutations and immunological mechanisms have promoted a better understanding of PP pathogenesis and might have important consequences on diagnostic refinement and treatment. In this narrative review, current findings in the pathogenesis, classification, clinical features, and therapeutic management of PP are briefly discussed.

show abstract

Section: Treatmentmentioning

confidence: 99%

Pustular Psoriasis: From Pathophysiology to Treatment

Genovese

Moltrasio

Cassano³

et al. 2021

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Regarding the evaluation of NPV, we suggest the authors employ ICD codes for all dermatology (ICD-10 L20-L30) 3 and the symptom of rash (e.g. ICD-10 T80Á6) to identify cases, and then review the record and evaluate the NPV.…”

Section: Response To 'mentioning

confidence: 99%

Response to: ‘Anakinra for palmoplantar pustulosis: results from a randomized, double‐blind, multicentre, two‐staged, adaptive placebo‐controlled trial (APRICOT)’: reply from the authors

Cro

Smith

2022

Br J Dermatol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Completed trials are summarized in Table 3. [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29][30] The first UK DCTN trial was on antibiotics to prevent cellulitis recurrences, and exemplifies the aims of the network. The idea came from a busy district hospital dermatologist (the late Dr Neil Cox 31 ) and evaluated a low-cost intervention (generic penicillin V) that is of little interest to industry, assessing it for a serious disease that did not seem to belong to any specialism.…”

Section: Where Do Patients Come Into It All?mentioning

confidence: 99%

Celebrating 20 years of the UK Dermatology Clinical Trials Network. Part 1: Developing and delivering high-quality independent clinical trials

Williams

McPhee

Layfield

2022

Clinical and Experimental Dermatology

View full text Add to dashboard Cite

Summary The UK Dermatology Clinical Trials Network (UK DCTN) was formed in 2002 with the aim of developing and supporting high‐quality independent national clinical trials that address prioritized research questions for people with skin disease. Its philosophy is to democratize UK dermatological clinical research and to tackle important clinical questions that industry has no incentive to answer. The network also plays a key role in training and capacity development. Its membership of over 1000 individuals includes dermatology consultants, trainees, dermatology nurses, general practitioners, methodologists and patients. Its organizational structures are lean and include a co‐ordinating team based at the Centre of Evidence‐Based Dermatology in Nottingham, and an executive with independent members to ensure probity and business progression. A prioritization panel and steering group enable a pipeline of projects to be prioritized and refined for external funding from independent sources. The UK DCTN has supported and completed 12 national clinical trials, attracting investment of over £15 million into UK clinical dermatology research. Trials have covered a range of interventions from drugs such as doxycycline (BLISTER), silk clothing for eczema (CLOTHES) and surgical interventions for hidradenitis suppurativa (THESEUS). Trial results are published in prestigious journals and have global impact. Genuine partnership with patients and carers has been a strong feature of the network since its inception. The UK DCTN is proud of its first 20 years of collaborative work, and aims to remain at the forefront of independent dermatological health technology assessment, as well as expanding into areas including diagnostics, artificial intelligence, efficient studies and innovative designs.

show abstract

Anakinra for palmoplantar pustulosis: results from a randomized, double‐blind, multicentre, two‐staged, adaptive placebo‐controlled trial (APRICOT)*

Cited by 25 publications

References 31 publications

Pustular Psoriasis: From Pathophysiology to Treatment

Pustular Psoriasis: From Pathophysiology to Treatment

Response to: ‘Anakinra for palmoplantar pustulosis: results from a randomized, double‐blind, multicentre, two‐staged, adaptive placebo‐controlled trial (APRICOT)’: reply from the authors

Celebrating 20 years of the UK Dermatology Clinical Trials Network. Part 1: Developing and delivering high-quality independent clinical trials

Contact Info

Product

Resources

About